Skip to main content

Table 2 The 10-year overall survival (OS) and thalassemia-free survival (TFS) in the study population

From: The effect of bone marrow-derived mesenchymal stem cell co-transplantation with hematopoietic stem cells on liver fibrosis alleviation and survival in patients with class III β-thalassemia major

All patients

OS (95% CI)

P value

TFS (95% CI)

P value

Mesenchymal group

No

61.89 (51.61–70.60)

0.294

52.78 (42.78–61.82)

0.285

Yes

71.84 (60.71–80.32)

63.64 (52.26–72.99)

Patient sex

Female

72.09 (6088–8059)

0.131

67.94 (56.79–76.79)

0.245

Male

61.06 (51.04–69.63)

59.35 (349.52–58.44)

Donor sex

Female

66.37 (54.58–75.77)

0.561

56.63 (45.15–66.59)

0.999

Male

65.78 (55.18–74.45)

57.66 (47.02–66.91)

Sex-matched

Mismatched

62.57 (50.93–72.19)

0.458

50.76 (39.58–60.90)

0.098

Matched

68.72 (58.29–77.05)

62.93 (52.49–71.69)

ABO-matched

ABO-matched

68.36 (58.15–76.58)

0.248

60.49 (50.36–69.19)

0.158

ABO-mismatched

62.17 (50.43–71.90)

51.65 (40.17–61.97)

Source of transplant

BM

72.82 (61.29–81.43)

0.194

61.96 (50.18–71.73)

0.492

PB

62.21 (52.58–70.43)

54.45 (44.95–63.01)

Acute GvHD

No

73.09 (62.21–81.30)

0.490

58.17 (47.36–67.51)

0.594

Yes

67.64 (59.42–71.51)

56.63 (46.41–65.62)

Chronic GvHD

No

64.29 (58.13–70.17)

0.867

68.02 (59.27–76.23)

0.341

Yes

68.46 (59.19–76.39)

73.46 (61.19–82.39)

  1. OS overall survival, TFS thalassemia-free survival, GvHD graft-versus-host disease, BM bone marrow, PB peripheral blood
  2. Log-rank test